Pulmonary Adverse Events in Patients Receiving Low‐Dose Methotrexate in the Randomized, Double‐Blind, Placebo‐Controlled Cardiovascular Inflammation Reduction Trial

Prespecified analysis (n=2391) found pulmonary adverse events (PAEs), including pneumonitis, were uncommon but were more likely to occur in those on low‐dose methotrexate (LDM). White race, older age, male sex, & insulin use were linked to increased risk of PAEs in those on LDM.

Source:

Arthritis & Rheumatology